Overexpression of miR-210 is associated with poor prognosis of acute myeloid leukemia

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 3427-3433

  Tang, Xiaoqiong ^a   Chen, Liping ^a   Yan, Xinyu ^a   Li, Yuanjie ^a   Xiong, Yuanlin ^a   Zhou, Xiaohui ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Acute; Leukemia; MicroRNAs; Myeloid; Prognosis

Indexed keywords

MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; UPREGULATION; BONE MARROW; CASE CONTROL STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE MARROW; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947435734     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894812     Document Type: Article

References (25)

1. Chen J, Odenike O, Rowley JD: Leukaemogenesis: more than mutant genes. Nat Rev Cancer, 2010; 10: 23-36
2. Verhaak RG, Valk PJ: Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. Cancer Treat Res, 2009; 145: 67-83
3. Min WL, Wang BF, Li J et al: The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res, 2014; 20: 97-104
4. Zhu C, Wang Y, Kuai W et al: Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem, 2013; 46: 49-53
5. Qian J, Lin J, Qian W et al: Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leuk Res, 2013; 37: 765-68
6. Chen XX, Lin J, Qian J et al: Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem, 2014; 47: 63-66
7. Qin Q, Furong W, Baosheng L: Multiple functions of hypoxia-regulated miR- 210 in cancer. J Exp Clin Cancer Res, 2014; 33: 50
8. Devlin C, Greco S, Martelli F, Ivan M: miR-210: more than a silent player in hypoxia. IUBMB Life, 2011; 63: 94-100
9. Chan SY, Loscalzo J: MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle, 2010; 9: 1072-83
10. Osugi J, Kimura Y, Owada Y et al: Prognostic impact of hypoxia-inducible miRNA-210 in patients with lung adenocarcinoma. J Oncol, 2015; 2015: 316745
11. Camps C, Buffa FM, Colella S et al: hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res, 2008; 14: 1340-48
12. Gee HE, Camps C, Buffa FM et al: hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010; 116: 2148-58
13. Papaconstantinou IG, Manta A, Gazouli M et al: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas, 2013; 42: 67-71
14. Mei Y, Gao C, Wang K et al: Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci, 2014; 105: 463-72
15. Macfarlane LA, Murphy PR: MicroRNA: biogenesis, function and role in cancer. Curr Genomics, 2010; 11: 537-61
16. Zhang Z, Sun H, Dai H et al: MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle, 2009; 8: 2756-68
17. Dang K, Myers KA: The Role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci, 2015; 16: 6353-72
18. Lai NS, Wu DG, Fang XG et al: Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer, 2015; 112(Suppl.): 1241-46
19. Zhan M, Li Y, Hu B et al: Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol, 2014; 25: 1279-87
20. Ho AS, Huang X, Cao H et al: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol, 2010; 3: 109-13
21. Wang J, Chen J, Chang P et al: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila), 2009; 2: 807-13
22. Samaan S, Khella HW, Girgis A et al: miR-210 is a prognostic marker in clear cell renal cell carcinoma. J Mol Diagn, 2015; 17: 136-44
23. Qu A, Du L, Yang Y et al: Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One, 2014; 9: e90952
24. Tsuchiya S, Fujiwara T, Sato F et al: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem, 2011; 286: 420-28
25. Eilertsen M, Andersen S, Al-Saad S et al: Positive prognostic impact of miR- 210 in non-small cell lung cancer. Lung Cancer, 2014; 83: 272-78